HU218103B - Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására - Google Patents

Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására Download PDF

Info

Publication number: HU218103B
Authority: HU; Hungary
Prior art keywords: dextran; interleukin; calcium salt; edta; composition
Prior art date: 1991-12-12

Application number

HU9203925A

Other languages

English (en)

Hungarian (hu)

Other versions

HU9203925D0 (en

HUT63575A (en

Inventor

Bruno Maneglier

Bernard Voncken

Original Assignee

HOECHST Marion Roussel S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-12

Filing date

1992-12-11

Publication date

2000-06-28

1992-12-11 Application filed by HOECHST Marion Roussel S.A. filed Critical HOECHST Marion Roussel S.A.

1993-03-29 Publication of HU9203925D0 publication Critical patent/HU9203925D0/hu

1993-09-28 Publication of HUT63575A publication Critical patent/HUT63575A/hu

2000-06-28 Publication of HU218103B publication Critical patent/HU218103B/hu

Links

101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title claims abstract description 19
102000055277 human IL2 Human genes 0.000 title claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 title claims description 18
238000000034 method Methods 0.000 title claims description 16
230000008569 process Effects 0.000 title claims description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 60
229920002307 Dextran Polymers 0.000 claims abstract description 55
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims abstract description 40
239000000203 mixture Substances 0.000 claims abstract description 38
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 20
229930195725 Mannitol Natural products 0.000 claims abstract description 20
239000000594 mannitol Substances 0.000 claims abstract description 20
235000010355 mannitol Nutrition 0.000 claims abstract description 20
108010002350 Interleukin-2 Proteins 0.000 claims description 37
102000000588 Interleukin-2 Human genes 0.000 claims description 37
JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical class O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 claims description 21
239000000539 dimer Substances 0.000 claims description 18
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 16
159000000007 calcium salts Chemical class 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 7
239000007864 aqueous solution Substances 0.000 claims description 5
230000000087 stabilizing effect Effects 0.000 claims description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 abstract 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 abstract 1
235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 abstract 1
239000003755 preservative agent Substances 0.000 abstract 1
230000002335 preservative effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 description 13
230000004071 biological effect Effects 0.000 description 12
238000004007 reversed phase HPLC Methods 0.000 description 10
FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 8
229940119743 dextran 70 Drugs 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
230000006641 stabilisation Effects 0.000 description 8
238000011105 stabilization Methods 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
239000003814 drug Substances 0.000 description 7
239000000126 substance Substances 0.000 description 7
230000000694 effects Effects 0.000 description 5
230000007774 longterm Effects 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
108010088751 Albumins Proteins 0.000 description 4
102000009027 Albumins Human genes 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000012535 impurity Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
238000003556 assay Methods 0.000 description 3
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 3
229940119744 dextran 40 Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
230000010412 perfusion Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
125000003396 thiol group Chemical group [H]S* 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000000356 contaminant Substances 0.000 description 2
239000013578 denaturing buffer Substances 0.000 description 2
229940000986 dextran 110 Drugs 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
239000008103 glucose Substances 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
CYWHLOXWVAWMFO-UHFFFAOYSA-N 3-sulfanyl-1h-pyridine-2-thione Chemical compound SC1=CC=CN=C1S CYWHLOXWVAWMFO-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000002109 Argyria Diseases 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000012615 aggregate Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000003275 alpha amino acid group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
108700003606 glycosylated interleukin 2 Proteins 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000012931 lyophilized formulation Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Cephalosporin Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HU9203925A 1991-12-12 1992-12-11 Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására HU218103B (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9115418A FR2684878B1 (fr)	1991-12-12	1991-12-12	Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.

Publications (3)

Publication Number	Publication Date
HU9203925D0 HU9203925D0 (en)	1993-03-29
HUT63575A HUT63575A (en)	1993-09-28
HU218103B true HU218103B (hu)	2000-06-28

Family

ID=9419958

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9203925A HU218103B (hu)	1991-12-12	1992-12-11	Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására

Country Status (18)

Country	Link
US (1)	US5340574A (de)
EP (1)	EP0554634B1 (de)
JP (1)	JP3291340B2 (de)
KR (1)	KR930012023A (de)
AT (1)	ATE135917T1 (de)
AU (1)	AU662940B2 (de)
CA (1)	CA2085142A1 (de)
DE (1)	DE69209486T2 (de)
DK (1)	DK0554634T3 (de)
ES (1)	ES2084965T3 (de)
FR (1)	FR2684878B1 (de)
GR (1)	GR3019440T3 (de)
HU (1)	HU218103B (de)
IL (1)	IL103862A (de)
MX (1)	MX9207199A (de)
RU (1)	RU2107511C1 (de)
UA (1)	UA26898C2 (de)
ZA (1)	ZA929627B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999018119A1 (en) *	1997-10-03	1999-04-15	Shionogi & Co., Ltd.	Process for freeze-drying proteins
DZ2788A1 (fr) *	1998-05-15	2003-12-01	Bayer Ag	Agonistes et antagonistes selectifs à IL-2.
CZ20021186A3 (cs) *	1999-10-04	2002-11-13	Chiron Corporation	Farmaceutické prostředky obsahující stabilizovaný kapalný polypeptid
RU2169004C1 (ru) *	1999-11-23	2001-06-20	Государственный научно-исследовательский институт особо чистых биопрепаратов	Ранозаживляющая композиция
DE602004019761D1 (de)	2003-01-08	2009-04-16	Novartis Vaccines & Diagnostic	Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
JP2008501639A (ja) *	2004-04-23	2008-01-24	ノベシンリミテッド	タンパク質を安定化、保護及び可溶化させるための方法及びキット
MX2007015039A (es) *	2005-06-06	2008-01-24	Novo Nordisk As	Composiciones de il-21 estabilizadas.
SG10201502398RA (en) *	2010-04-27	2015-05-28	Scil Technology Gmbh	Stable MIA/CD-RAP formulations

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE251001C (de) *
FR353150A (fr) *	1905-04-08	1905-09-04	Gerardo Caffaro	Compteurs à gaz
FR452598A (fr) *	1912-12-26	1913-05-19	Lanston Monotype Corp Ltd	Perfectionnements apportés aux machines servant à la composition typographique
JPS61500790A (ja) *	1984-03-28	1986-04-24	シタス　コ−ポレイシヨン	微生物的に製造されたインターロイキン―２を含有する組成物
EP0158487B1 (de) *	1984-04-09	1991-08-28	Takeda Chemical Industries, Ltd.	Stabile Interleukin-2-Zusammensetzung
US4572798A (en) *	1984-12-06	1986-02-25	Cetus Corporation	Method for promoting disulfide bond formation in recombinant proteins
US4748234A (en) *	1985-06-26	1988-05-31	Cetus Corporation	Process for recovering refractile bodies containing heterologous proteins from microbial hosts
US4816440A (en) *	1985-09-26	1989-03-28	Cetus Corporation	Stable formulation of biologically active proteins for parenteral injection
DK585886A (da) *	1985-12-24	1987-06-25	Takeda Chemical Industries Ltd	Immunstimulerende middel og anvendelse deraf
JPH0645551B2 (ja) *	1986-01-07	1994-06-15	塩野義製薬株式会社	インタ−ロイキン−２組成物
US4933433A (en) *	1986-01-31	1990-06-12	E. I. Du Pont De Nemours And Company	Recombinant interleukin-2 composition and process for making it
DE3621828A1 (de) *	1986-06-28	1988-01-14	Biotest Pharma Gmbh	Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4931544A (en) *	1986-09-04	1990-06-05	Cetus Corporation	Succinylated interleukin-2 for pharmaceutical compositions
US5037644A (en) *	1986-10-27	1991-08-06	Cetus Corporation	Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4931543A (en) *	1987-05-11	1990-06-05	Cetus Corporation	Process for recovering microbially produced interleukin-2
US4863726A (en) *	1987-05-29	1989-09-05	Cetus Corporation	Combination therapy using immunotoxins with interleukin-2
US5004605A (en) *	1987-12-10	1991-04-02	Cetus Corporation	Low pH pharmaceutical compositions of recombinant β-interferon
US5215743A (en) *	1988-04-13	1993-06-01	Maninder Singh	Tumor necrosis factor formulations
US5078997A (en) *	1988-07-13	1992-01-07	Cetus Corporation	Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
FR2635527B1 (fr) *	1988-07-28	1992-06-12	Roussel Uclaf	Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
US4902502A (en) *	1989-01-23	1990-02-20	Cetus Corporation	Preparation of a polymer/interleukin-2 conjugate
FR2660863B1 (fr) *	1990-04-17	1994-01-21	Roussel Uclaf	Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5204094A (en) *	1991-01-17	1993-04-20	Roussel Uclaf	Treatment of pneumothorax

1991
- 1991-12-12 FR FR9115418A patent/FR2684878B1/fr not_active Expired - Fee Related
1992
- 1992-11-24 IL IL10386292A patent/IL103862A/xx not_active IP Right Cessation
- 1992-12-10 AU AU30041/92A patent/AU662940B2/en not_active Ceased
- 1992-12-11 US US07/989,230 patent/US5340574A/en not_active Expired - Lifetime
- 1992-12-11 KR KR1019920023909A patent/KR930012023A/ko not_active Ceased
- 1992-12-11 CA CA002085142A patent/CA2085142A1/fr not_active Abandoned
- 1992-12-11 EP EP92403362A patent/EP0554634B1/de not_active Expired - Lifetime
- 1992-12-11 DK DK92403362.4T patent/DK0554634T3/da active
- 1992-12-11 AT AT92403362T patent/ATE135917T1/de not_active IP Right Cessation
- 1992-12-11 DE DE69209486T patent/DE69209486T2/de not_active Expired - Lifetime
- 1992-12-11 ES ES92403362T patent/ES2084965T3/es not_active Expired - Lifetime
- 1992-12-11 ZA ZA929627A patent/ZA929627B/xx unknown
- 1992-12-11 HU HU9203925A patent/HU218103B/hu not_active IP Right Cessation
- 1992-12-11 RU RU92004553A patent/RU2107511C1/ru active
- 1992-12-11 JP JP35229692A patent/JP3291340B2/ja not_active Expired - Lifetime
- 1992-12-11 MX MX9207199A patent/MX9207199A/es not_active IP Right Cessation
1993
- 1993-06-08 UA UA93002691A patent/UA26898C2/uk unknown
1996
- 1996-03-28 GR GR950402527T patent/GR3019440T3/el unknown

Also Published As

Publication number	Publication date
IL103862A (en)	1997-02-18
ES2084965T3 (es)	1996-05-16
MX9207199A (es)	1993-07-01
RU2107511C1 (ru)	1998-03-27
AU3004192A (en)	1993-06-17
JPH05345728A (ja)	1993-12-27
DK0554634T3 (da)	1996-07-01
DE69209486D1 (de)	1996-05-02
US5340574A (en)	1994-08-23
CA2085142A1 (fr)	1993-06-13
ATE135917T1 (de)	1996-04-15
GR3019440T3 (en)	1996-06-30
FR2684878A1 (fr)	1993-06-18
DE69209486T2 (de)	1996-09-12
JP3291340B2 (ja)	2002-06-10
HU9203925D0 (en)	1993-03-29
AU662940B2 (en)	1995-09-21
EP0554634B1 (de)	1996-03-27
FR2684878B1 (fr)	1994-02-11
HUT63575A (en)	1993-09-28
ZA929627B (en)	1993-12-13
IL103862A0 (en)	1993-04-04
KR930012023A (ko)	1993-07-20
EP0554634A1 (de)	1993-08-11
UA26898C2 (uk)	1999-12-29

Legal Events

Date	Code	Title	Description
1999-04-28	DGB9	Succession in title of applicant	Owner name: HOECHST MARION ROUSSEL S.A., FR
2001-08-28	HMM4	Cancellation of final prot. due to non-payment of fee

Publication	Publication Date	Title
KR100266145B1 (ko)	2000-09-15	G-csf의 안정한 동결건조된 약제학적 제제
US5919757A (en)	1999-07-06	Aqueous pharmaceutical preparations of G-CSF with a long shelf life
ES2224290T5 (es)	2012-03-12	Formulaciones l�?quidas estables de interferón.
DE69432179T2 (de)	2003-07-24	Eine formulierung des gerinnungsfaktors viii
EP1180368B1 (de)	2007-04-18	Gefriergetrocknete hgf-präparationen
JP3530300B2 (ja)	2004-05-24	安定なトランスグルタミナーゼ製剤およびそれらを製造する方法
KR20110086583A (ko)	2011-07-28	제8 인자 제형
PT2720710E (pt)	2016-06-17	Formulações liofilizadas de fgf-18
EA030220B1 (ru)	2018-07-31	Устойчивая жидкая композиция, содержащая amg-416 (этелкалцетид)
EP1750751A1 (de)	2007-02-14	Stabilisierte flüssige interferon-formulierungen
EP0391444A2 (de)	1990-10-10	Interleukin-1 Formulierung
JPH05331071A (ja)	1993-12-14	カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法
EP1029548B1 (de)	2007-04-04	Verfahren zur qualitätssicherstellung von wässrigen parenteralen lösungen mit thrombomodulin in der lagerung und verteilung
PT759775E (pt)	2000-11-30	Formulacoes liquidas de ifn-b
HU218103B (hu)	2000-06-28	Nem-glikozilezett, rekombináns humán interleukin-2 redukált alakját tartalmazó, stabilizált gyógyászati készítmény és eljárás előállítására
AU2017225236B2 (en)	2022-03-31	A lyophilised pharmaceutical formulation and its use
US5534251A (en)	1996-07-09	Stabilized il-1α medicinal composition
RU94042742A (ru)	1997-06-10	Препарат генно-инженерного гамма-интерферона
AU629549B2 (en)	1992-10-08	Homogeneous dimeric m-csf and storage stable formulations thereof
Allen et al.	1999	Hybrid (BDBB) interferon-α: preformulation studies
JPH06247870A (ja)	1994-09-06	インターロイキン−６を含有する医薬製剤
KR20060108040A (ko)	2006-10-17	인 과립구 콜로니 자극인자 용액 제형